Financials
Financial year 2025
SMECE Acute Medicine from Erpe-Mere, company number BE0737434481, closed financial year 2025 with a result of € 27,491 after tax. For that financial year SMECE Acute Medicine recorded a gross margin of € 35,299 and equity of € 35,572. Compared with financial year 2024, the result moved from € 38,231 to € 27,491. The company is profitable. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 29, 2026.
€ 35,572
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 27,491
▼ 28% vs 2024
Profit after tax over the fiscal year.
€ 32,533
▲ 52% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 27,491 paid out
100 % of the profit went to the shareholders, the rest stayed in the company.
People and assets in 2025
≈ 1
No payroll staff. One director, so that person most likely runs the business.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 323
Supplier invoices still open on the last day of the fiscal year.
€ 10,629
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 21,006 | € 46,256 | € 52,555 | € 35,299 | ▼ 33% |
| Profit after taxes | € 10,285 | € 31,074 | € 38,231 | € 27,491 | ▼ 28% |
| Equity | € 35,572 | € 35,572 | € 35,572 | € 35,572 | |
| Total debts | € 5,434 | € 44,954 | € 39,767 | € 40,762 | ▲ 3% |
| Cash | € 18,182 | € 41,724 | € 21,386 | € 32,533 | ▲ 52% |
| Retained profit | € 34,572 | € 34,572 | € 34,572 | € 34,572 | |
| Dividend | € 0 | € 31,074 | € 38,231 | € 27,491 | ▼ 28% |
| Balance sheet total | € 41,006 | € 80,526 | € 75,339 | € 76,334 | ▲ 1% |
Key figures of SMECE Acute Medicine, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
Ask about SMECE Acute Medicine the way you would ask their accountant.
Answers from the filed annual accounts, the Belgian Official Gazette and the CBE register.
Connect ChatGPT or Claude for free- ChatGPT
- Claude
Free account, no payment card. Key figures unlimited, the annual accounts and deeds of 10 companies a month. Need more? Get in touch, we are looking for our first pilot users.
What happened to SMECE Acute Medicine?
What happened at SMECE Acute Medicine in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 27,491 (▼ 28% vs 2024). Source: NBB ↗
- Incorporation, published in the Gazette. Source: Staatsblad ↗
- New establishment in Erpe-Mere. KBO
- Cedric Smets became a director. NBB
In short
From € 10,285 profit in 2022 to € 27,491 profit in 2025.
Paid € 41,420 in corporate taxes since 2022.
Best year ever: 2024, with € 38,231 profit.
Paid out € 96,796 in dividends to the owners in total.
Management
Behind SMECE Acute Medicine is Cedric Smets.
Directors
According to the 2025 annual accounts
Cedric Smets
Director
since 2019
Establishments
Establishment units
Physical locations of this company
Populierenstraat 39
9420 Erpe-Mere
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Shareholders according to the Official Gazette deeds
Who contributed at incorporation and at capital increases, with the deed as source. Later share transfers are not published in the Gazette.
Incorporation
Source: Deed ↗- SMETS Cedric Elisabeth Willy(oprichter) 100%
Details
- Company number
- 0737.434.481
- VAT number
- BE 0737.434.481
- Registered office
- Populierenstraat 39, 9420 Erpe-Mere
- Names & denominations
- SMECE Acute Medicine
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 6 November 2019
- Peppol
- Active · Active since 15 Apr 2026
- Contact
- [email protected]